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Abstract
West Nile virus infection (WNV) is an emerging mosquito-borne disease that can lead to severe
neurological illness and currently has no available treatment or vaccine. Using microengraving, an
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integrated single-cell analysis method, we analyzed a cohort of subjects infected with WNV recently infected and post-convalescent subjects - and efficiently identified four novel WNV
neutralizing antibodies. We also assessed the humoral response to WNV on a single-cell and
repertoire level by integrating next generation sequencing (NGS) into our analysis. The results
from single-cell analysis indicate persistence of WNV-specific memory B cells and antibodysecreting cells in post-convalescent subjects. These cells exhibited class-switched antibody
isotypes. Furthermore, the results suggest that the antibody response itself does not predict the
clinical severity of the disease (asymptomatic or symptomatic). Using the nucleotide coding
sequences for WNV-specific antibodies derived from single cells, we revealed the ontogeny of
expanded WNV-specific clones in the repertoires of recently infected subjects through NGS and
bioinformatic analysis. This analysis also indicated that the humoral response to WNV did not
depend on an anamnestic response, due to an unlikely previous exposure to the virus. The
innovative and integrative approach presented here to analyze the evolution of neutralizing
antibodies from natural infection on a single-cell and repertoire level can also be applied to
vaccine studies, and could potentially aid the development of therapeutic antibodies and our basic
understanding of other infectious diseases.

Keywords
Emerging infectious disease; flavivirus; humoral immunity; antigen specific; microengraving;
repertoire sequencing
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Author Manuscript

West Nile virus (WNV) is a mosquito-borne, enveloped positive-strand RNA virus that can
lead to severe neurological disease. The virus belongs to the family flaviviridae, which
includes yellow fever, hepatitis C virus, and dengue viruses 1,2. The emergence of WNV in
North America was first documented in 1999 in New York, USA. WNV has now become
established throughout the USA and has spread into Canada, Mexico, and the Caribbean.
Reports from the CDC indicate infection of more than 41,000 people to date, including more
than 1,700 fatalities 3. The cumulative incidence of WNV infection may reach 3 million
people 2,4. Currently, there is no approved treatment or vaccine against WNV 1,2,5.

Author Manuscript

Passive administration of neutralizing antibodies (NAbs) is one possible route to treat viral
infections 6,7 and could have therapeutic value in the context of severe flavivirus
infection 8–11. WNV-specific NAbs have been derived by phage and yeast display libraries
from both humans and mice 12–16. Murine antibodies have shown potency in mouse models,
but the epitopes targeted by this class of antibodies comprise only a minor component of the
neutralizing response in humans. These antibodies have limited utility as therapeutics to
date 17. Other disadvantages of library-based methods to derive NAbs are the random
pairing of heavy- and light-chains, which obscures the natural humoral response, involves
time-consuming assays, and identifies antibodies with limited neutralization function 18. In
contrast, recent studies have identified a large number of highly potent human
immunodeficiency virus-1 (HIV-1) specific NAbs directly derived from HIV-infected
patients using flow cytometry to sort memory B cells (MBCs) based on their affinity to HIV
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antigens 19,20. For potential vaccine strategies, WNV-specific NAbs directly derived from
humans could also reveal information about naturally targeted epitopes on the virus. NAbs,
however, are only a part of the humoral immune response to WNV. For a better
understanding of antibody-mediated mechanisms involved, such as disease outcome or
persistence of antibodies and virus 21, our analysis of the humoral response should span
from single cells to the level of the antibody repertoire.

Author Manuscript

In contrast to HIV or influenza, the prevalence of WNV is low and many cases are
undiagnosed, making it challenging to assemble a large WNV cohort. Despite these
obstacles, we effectively discovered and evaluated four novel NAbs against WNV directly
from rare WNV-specific human B cells isolated from a set of recently infected and postconvalescent subjects. For this purpose, we combined microengraving 22–24, an integrated
multiparameter single-cell analysis method and next-generation sequencing (NGS). We
analyzed activated memory B cells (MBCs) and antibody-secreting cells (ASCs) from blood
on a single-cell level and evaluated the relationship of the parental WNV-specific clones
within the circulating repertoire of B cells (Fig. 1). Despite a low frequency of WNVspecific B cells (mean <24 Ag+ events per 100,000 PBMCs), these methods for integrated
analysis allowed us to obtain NAbs and enabled analysis of the humoral response to WNV
on a single-cell and repertoire level. The single-cell analysis revealed rare but persistent
WNV-specific MBCs and ASCs in post-convalescent subjects. Furthermore, the results
presented here indicate that the antibody response is independent of an asymptomatic vs.
symptomatic disease outcome, as we have noted previously 25. Using the nucleotide coding
sequences for WNV specific antibodies discovered from single cells, we also revealed
expanded WNV specific clones in the repertoires of recently infected subjects through NGS
and bioinformatic analysis.

Author Manuscript

Results
Identification of study subjects with high serum neutralizing antibody titers and profiling
of their West Nile virus-specific humoral response

Author Manuscript

To examine developing humoral responses to WNV, we recruited a cohort of recently
infected subjects during the 2012 WNV outbreak in Houston, Texas (Table 1). Blood
samples were collected at two time points, 1.9 ± 0.8 months post onset (range 0.8–2.9; n=7)
and 3.2 ± 1.2 months (range 2–4.7; n=6, one subject lost to follow-up) after infection. Both
time points correspond to samples of the recently infected period following exposure to
WNV. To identify post-convalescent subjects with high serum neutralizing antibody titers,
we screened our cohort of more than 160 WNV subjects who we have monitored since
2002 26. We initially selected individuals from asymptomatic and severe infection groups
with a history of exposure less than 2 years after infection with WNV (total n=17, enrolled
n=4). We quantified anti-WNV antibodies by immunoblot and an antibody neutralization
assay from four post-convalescent subjects; all four exhibited high serum neutralizing
antibodies (1:80), with the highest neutralization score found (1:640) in an asymptomatic
subject. In addition, we measured the serum antibody isotype concentrations among the
recently infected subjects and found no deviation from standard values (IgM 40–230 mg/dL,
IgA 70–400 mg/dL, and IgG 700–1600 mg/dL) 27, indicating a normal antibody response.
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Further, immunophenotyping of surface markers28 showed no significant differences
between the frequencies of naïve B cells, MBCs, and plasmablasts of recently infected and
post-convalescent subjects in this study (Fig. 2). Notably we found significant differences
comparing the recently infected subjects to a separate cohort of post-convalescent subjects
from a previously published study (ImmPort study identification number SDY58)29. The
current cohort of post-convalescent subjects with high serum neutralizing antibody titers
showed slightly different frequencies of transitional B cells, plasma blasts and memory B
cells, which may be due to the shorter convalescent period or the smaller sample size
between the two groups of post-convalescent subjects. In total, we identified 11 subjects
from our cohort of varying age, gender, disease outcome, and disease stage for our study.
West Nile virus neutralizing antibodies identified by single-cell analysis

Author Manuscript
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Using microengraving 23,24 (Fig. 1), we recovered more than 90 WNV-specific single
MBCs and ASCs (S 1). From those cells, we recovered 19 antibody-coding sequences where
both heavy (V1, V3, V4 V region family) and light (V1, V2, V3 V region family) chains
were present after PCR amplification. These 19 paired antibody-coding sequences were used
for cloning and further evaluation (S 2). We found no significant difference (p>0.05) in the
amount of selection pressure between MBCs and ASCs by analyzing the mutations in the
complementarity-determining (CDR) and framework (FWR) regions 30. Of the 19 recovered
antibodies, twelve expressed with sufficient amounts of protein for further evaluation by
immunoblot (S 3), plaque reduction neutralization assay (PRNT), and protein binding assays
to determine their relative affinities (Table 2). As controls, we used serum from WNV
positive (HS+) and WNV negative (HS−) subjects, and an antibody (2G12) with known
affinity to HIV-1. Of the WNV-specific antibodies, five were from post-convalescent and
seven from recently infected subjects. Three expressed antibodies showed reactivity to
WNV envelope (E) protein by immunoblot, and four also showed efficient neutralization of
WNV. Interestingly, three of the neutralizing antibodies did not show reactivity to WNV E
protein by immunoblot, suggesting that they recognize conformation-dependent epitopes.
Antibody MIT89 was positive both by immunoblot and PRNT. Furthermore, we observed a
positive trend between the relative antibody affinities for WNV E protein and WNV
neutralization. All neutralizing antibodies were recovered exclusively from postconvalescent subjects.
West Nile virus-specific B cells in circulation are persistent and disease severity is
independent of the humoral immune response

Author Manuscript

To determine whether elevated levels of WNV specific B cells persist in post-convalescent
subjects, we used the results obtained by single-cell analysis to determine the frequencies of
WNV-specific MBCs and ASCs (Fig. 3) in circulation. The overall mean frequency and
SEM across all subjects for the MBCs and the ASCs was 23.4 ± 9.7 and 8.4 ± 3.4 per
100,000 PBMCs, respectively. We found no significant difference between recent and postconvalescent WNV-infected individuals in the frequencies of either PBMC-derived MBCs
(p=0.61) or ASCs (p=0.64). Nevertheless, we observed a lower mean frequency (per
100,000 PBMCs) in the MBC post-convalescent population (Δμ =11). These results suggest
that the frequencies of WNV-specific MBCs and ASCs decrease after the acute phase of
infection, but still persist in circulation. These data provide a direct measure of the
Integr Biol (Camb). Author manuscript; available in PMC 2016 December 30.
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frequencies of WNV-specific B lymphocyte persistent in circulation of subjects with a
history of WNV infection. These findings are consistent with our results of frequencies of B
lymphocytes detected by flow cytometry of cells from recently infected and postconvalescent subjects (Fig. 2). These results are also consistent with previous reports of
long-term persistence of WNV specific antibodies in serum 26,31,32.

Author Manuscript

We tested whether there were significant differences between MBC or ASC frequencies
according to disease outcome (severely infected vs. asymptomatic) (Fig. 3) or according to
age (<40 vs. 40–60 vs. >60 years) (S 4). There were no significant differences (p=0.92)
between the frequencies of antigen-specific MBCs in symptomatic (24.2 ± 14.7, n=7) and
asymptomatic individuals (22.1 ± 10.8, n=4), providing evidence that the frequency of B
cells was not associated with the severity of WNV disease. We did, however, detect a
significant increase in the frequencies of MBCs for subjects >60 years compared to the other
age groups (p<0.05). The results presented here suggest persistence of WNV-specific
antibodies in post-convalescent subjects. Furthermore, the data indicate that the WNVspecific antibody response does not predict the clinical outcome of asymptomatic or
symptomatic disease as noted previously 25,29.
Distribution of isotypes corresponds to those in serum
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We quantified the distribution of isotypes (IgM, IgA, IgG1, and IgG3) from activated MBCs
and ASCs of recently infected subjects by microengraving (S 5). Overall, no significant
differences were detected between severely infected and asymptomatic subjects among
either MBCs or ASCs. We found elevated ratios of IgM to IgG1 in three of the four severely
infected subjects (S 5A). As expected, we also found significantly higher levels of IgG1
compared to the other three isotypes among MBCs (S 5B–D). We observed slightly
increased percentages of IgG3 among ASCs. Overall, the distributions of antibody isotypes
we observed by microengraving were as expected based on the isotype distributions
determined from serum found in other viral infections 33.
Next generation sequencing of B cell repertoires reveals clonal expansion in individuals
recently infected with West Nile virus

Author Manuscript

To gain a better understanding of the overall variance among the B cells in circulation, we
sequenced the B cell heavy chains from PBMCs, naïve, and memory B cell populations of
seven recently infected subjects (S 6). The distributions of isotypes determined by NGS of
PBMCs and MBCs showed no significant differences between asymptomatic and
symptomatic recently infected subjects, confirming the results measured from individual
cells by microengraving (S 7). To identify WNV-specific clones in the repertoire, the
individual WNV-specific antibody sequences obtained by the single-cell analysis (“queries”)
were combined with the NGS data and groups of clonally-related sequences were
automatically identified using Change-O as described in methods 34. This method identified
three expanded clones that included one of the query sequences. To identify additional
WNV-specific clones, the sequences from the NGS were plotted based on their level of
mutation and similarity to each of the query antibody sequences (Fig. 4 & S 9). The three
WNV-specific clones were clearly identifiable as outlier groups of sequences with higher
similarity to the queried WNV-specific antibody sequences compared to other sequences
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with a similar level of mutation (Fig. 4B & S 9). In addition, manual inspection of these
plots identified two additional WNV-specific clones. The WNV-specific clones showed
evidence of expansion, and sequences were found both among PBMCs and memory B cells
with both IgA and IgG isotypes. Overall, five WNV-specific clones were identified through
integration of the single-cell analysis and NGS data. The frequency of all expanded clones
and degree of mutations in recently infected subjects is shown in Figure (S 8).

Author Manuscript
Author Manuscript

Since WNV is a recent pathogen to North America, the WNV-specific clones we identified
are likely a result of a primary immune response originating from naïve B cells, rather than a
recall response from memory B cells. Therefore, we hypothesized that the WNV-specific
clonal expansion we observed would have initiated from less affinity-matured cells than
those that generate antigen-specific clones after a recall response to re-occurring infections
or vaccinations to viruses such as influenza. To investigate this hypothesis, we approximated
the sequence of the initiating B cell for each clone as the most recent common ancestor in a
maximum parsimony lineage tree (Fig. 4C & S 10). Maximum parsimony lineage trees
minimize the number of mutation events in each clone and infer sequences that may have
existed between observed antibodies and the germline sequence. The trunk length of the
lineage tree (i.e., the number of mutations in the most recent common ancestor compared
with the germline sequence) approximates the maturation state of the initiating B cell for
each clone. In comparison to other similarly sized B cell clones in the recently infected
WNV subjects, the trunks in WNV-specific clones had significantly (p < 0.05) fewer
mutations (Fig. 4D). It is possible, however, that some of the similarly-sized clones in this
cohort are WNV-specific, which could confound the comparison. To address this issue, we
also compared the trunk lengths in WNV-specific clones with expanded (at least 0.05% of
the repertoire) clonal lineages from three responses following influenza vaccination,
obtained from publicly available data 35. We found that the WNV-specific clones once again
had trunks that were significantly (p < 0.05) less mutated than those found from the
influenza response. The close mutational distance of sequences that give rise to WNVspecific B cell clones to their respective germlines supports our hypothesis that these
subjects have not previously been exposed to WNV and have experienced primary affinity
maturation rather than a recall response. In the case of two clones (MIT187 and MIT180) (S
10), the query sequence was not a terminal leaf; other sequences with additional mutations
were observed in the lineage tree. Antibodies both more and less mutated than the query
sequences could also show high affinity and neutralizing activity to WNV. This general
approach of using specific antibodies found by microengraving as query sequences to reveal
similar antibodies at the repertoire level could have wide applications for a larger scale
search for therapeutic neutralizing antibodies specific to many other diseases.

Author Manuscript

Discussion
In this study, we analyzed PBMCs from individuals with recent or post-convalescent WNV
infections. We effectively identified WNV-specific antibodies by single-cell analysis. We
next cloned and expressed the antibodies identified by single-cell analysis and performed
PRNT, to identify WNV-specific NAbs. Four of the NAbs identified also showed high
affinity to WNV E protein as determined by protein microarray. In contrast, only one NAb
was also positive in the immunoblot assay. These results may indicate that three of the
Integr Biol (Camb). Author manuscript; available in PMC 2016 December 30.
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discovered NAbs recognize conformation dependent epitopes on the WNV E protein that
could have been denatured during the immunoblot assay 36. Similarly, antibodies to the
related Flavivirus family member dengue virus, a quaternary epitope was required for
neutralization of the virus 9, indicating that denaturing of the higher order antibody protein
structure could result in a loss of function. We also observed that neutralizing activity was
positively correlated with increased antibody affinity to WNV E protein. This trend suggests
that the development of NAbs in WNV infection requires a high degree of affinity
maturation. In support of this hypothesis, we found NAbs exclusively in the postconvalescent subjects, which could indicate that the detected antibodies developed later
during the course of infection, and that they require a prolonged exposure to antigen to
promote affinity maturation. Chronic or repeated exposure to viral antigens such as HIV-1
can elicit affinity maturation beyond the degree observed here 19. In contrast to previously
identified NAbs derived using murine phage and yeast display libraries 12–16, the antibodies
here were directly derived from human B cells obtained from individuals previously infected
with WNV. These antibodies therefore reflect the natural selection and maturation of WNVspecific NAbs in humans. The challenge here exists in identifying the rare B cells producing
NAbs. For instance, in infections with the dengue virus, a related flavivirus, only a small
fraction of the antibodies expressed strongly neutralized the virus 8 although recent studies
have identified an epitope that may be relevant for effective neutralization 37. This outcome
highlights the importance of utilizing single-cell analysis methods to identify rare B cells of
interest. Future studies should further elucidate the epitopes and mechanisms of action of the
NAbs identified here. In addition, developing and validating a small animal model and
testing these antibodies could provide evidence for potential therapeutic use.
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This study marks the first time that the frequencies of circulating WNV-specific MBCs and
ASCs were determined. We observed no significant difference between the frequencies in
post-convalescent subjects compared to recently infected subjects, indicating potential longterm persistence of antigen specific MBCs and ASCs in WNV infection (Fig. 3). These
results have limited power due to the relatively small sample size of four post-convalescent
subjects and seven recently infected subjects. However, they are supported by previous
studies where WNV-specific serum antibodies were detected in subjects up to 8 years postinfection 26,31,32,36,38. Persistence of serum antibodies specific to other viral infections and
vaccines (e.g. dengue, influenza, and measles) have also been previously observed 8,39–41
and are well documented in the case of the related hepacivirus hepatitis C 42,43. Repeated
acute exposure to WNV is unlikely due to the low prevalence of this flavivirus 2,4. Chronic
exposure to the viral envelope from an unknown reservoir has also been suggested by other
recent studies 21,26.
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Though previous longitudinal studies of the immune response to influenza vaccination
indicate that clonal expansion occurs seven days post-vaccination 35,44,45, the recently
infected subjects in this study had been infected with WNV at least four weeks prior to the
first blood draw. The expansion of WNV-specific clones in comparison with postconvalescent subjects exposed to WNV years prior to sampling implies that the antibodymediated response may persist longer than in the case of other infections or vaccines.
Chronic infections have been shown to lead to expanded B cell clones in the case of
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cytomegalovirus (CMV) or clones with higher levels of mutations in the case of EpsteinBarr virus (EBV) 46.
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To date, it has not been thoroughly described how the nature and role of the humoral
response to WNV affects clinical manifestation of the disease, although we have recently
identified a transcriptional signature of susceptibility to severe disease 29. The results
presented here (Fig. 3) support our previous results that the levels of antibodies to WNV
were not significantly different between asymptomatic and severely infected subjects 25.
These findings show that, although WNV infection induces a humoral response, the level of
the anti-viral antibody titers is not a distinguishing feature of disease severity. This
observation has also been noted for antibody levels in humans infected with a related
hepacivirus, hepatitis C virus, for which antibody responses also fail to predict the clearance
of infecting virus 42,43. Our data suggest that the pathways needed to mount a successful
antibody response remain intact and that the mechanisms leading to severe disease are
independent of these pathways. Further supporting this hypothesis, all study subjects showed
serum isotype (IgM, IgA, IgG) titers in the normal range, indicating that B cell function and
class switching were intact. Interestingly, we found increased levels of activated IgA MBCs
in severely infected subjects. Class switching following the progression of WNV infection
has been described as an initial increase in IgM and IgA, followed by a decrease in IgM and
an increase in IgG 26,47. We postulate that our observed increased ratio of IgM/IgG1 in
severely infected subjects could therefore indicate a delayed immune response to WNV
infection and that the kinetics of this lag could trend with clinical severity.

Author Manuscript
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In summary, we effectively identified novel human-derived NAbs and analyzed the humoral
response to WNV infection by integrating single-cell analysis, repertoire next generation
sequencing, and conventional methods. Detecting persistent antigen-specific MBCs and
ASCs in the periphery of post-convalescent subjects can reveal the origin of these antibodies
and potentially provide clues about the persistence of WNV in the body. We believe that
WNV provides an excellent model to examine primary naïve responses of human B cells,
given the disease’s well-defined clinical history for the onset of infection, the low
occurrence of infection by this or others flaviviruses (e.g., dengue) in North America, which
allows the characterization of naïve responses to a recently introduced pathogen with
unlikely re-exposure. Our results comparing the distances of inferred clonal founder cells
from their respective germlines support the hypothesis that WNV-specific antibodies
develop from naïve B cells during a primary infection, rather than a recall response from an
affinity matured memory B cells. These results highlight the importance of analyzing the
immune response to infection with integrated single-cell data, serum analysis, and whole
repertoire analysis. These methods to analyze the humoral response can also be applied to
other infectious diseases research and in vaccine trials.

Material and methods
Recruitment of Human Subjects and Sample Validation
Human subjects exhibiting various WNV infection phenotypes were recruited from a wellcharacterized cohort of volunteers. Blood was obtained with written informed consent under
the guidelines of the Human Investigations Committee of Baylor College of Medicine,
Integr Biol (Camb). Author manuscript; available in PMC 2016 December 30.
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which approved the study. Investigation of coded samples was approved by Yale University
and Massachusetts Institute of Technology in compliance with HIPAA guidelines. The
diagnosis of WNV infection was determined following CDC guidelines 48 and subjects were
stratified by CDC definitions to a severe neuroinvasive phenotype, mild fever-only
phenotype, or asymptomatic infection as described previously 48. Infection was validated by
qualitative rapid nucleic acid test at the blood bank (cobas®TaqScreen West Nile virus Test,
Roche Molecular Systems, Pleasanton, CA), positive immunoblot as described
previously 25, or IgM ELISAs. Subjects (n=11) were 45.5% female and 90.9% white and
included asymptomatic, mild, and severe patients. Subjects from the asymptomatic, mild,
and severely infected groups were not statistically different for age, gender, or race in this
study.
Preparation of blood cells, B cell sorting, and Immunophenotyping

Author Manuscript

Blood samples were collected in CPT tubes (Becton Dickinson and Co., Franklin Lakes, NJ)
according to the manufacturer’s instructions (including centrifugation within 2 hours of
collection) and were processed the following day.
Serum was collected separately and stored at −80°C until assay 25. Peripheral blood
mononuclear cells (PBMCs) were sorted fresh to obtain B cell subsets.

Author Manuscript

For B cell subset sorting, fresh PBMCs were enriched using anti-CD20 magnetic beads
(Stemcell Technologies Inc., Vancouver, BC, Canada). PBMCs were stained on ice with
anti-human antibodies (Becton Dickinson and Biolegend) and directly coupled to either
CD19-Pacific Blue, CD21-allophycocyanin (APC), IgM-fluorescein-isothiocyanate (FITC),
CD10-phycoerythrin-Cy7 (PE-Cy7), CD27 (PuCL45.5), CD138- phycoerythrin (PE), to
distinguish among individual B cell subpopulations 49,50. B cells were sorted on a
FACSAria (Becton Dickinson). Cells were pelleted and frozen in lysate buffer (Ambion
mirVana™ miRNA Isolation Kit, Life Technologies, Grand Island, NY) and RNA was
isolated according to the manufacturer’s instructions. For multiparameter robotic
immunophenotyping, frozen PBMCs were thawed in one batch, washed, dispensed into
wells, and incubated with antibody panels using a custom programmed BioMek robotic
platform prior to FACS analysis using the LSR Fortessa (BD BioSciences) as described 29.
Antibody markers included 8 panels of which 5 were defined by the Human
Immunophenotyping Consortium (HIPC; www.immuneprofiling.org/hipc/page/show) 28.
The B lymphocyte panel consists of CD24, CD19, CD27, CD38, CD20, CD3 and IgD.
WNV immunoblot and neutralization assays

Author Manuscript

Antibody titer from human sera was quantified by immunoblot against WNV recombinant
envelope (E) protein and by quantitative virus-specific plaque-reduction neutralization test
(PRNT) assay as described 51. WNV studies were conducted in a Biosafety Level 3 facility,
licensed by the State of Connecticut and Yale University. Virulent WNV (CT-2741)
provided by Dr. John Anderson, Connecticut Agricultural Experiment Station, New Haven,
CT 52 was passaged once in Vero cells (ATCC CCL-81).
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Actively secreting and memory B cell populations in PBMC samples obtained from subjects
were analyzed by microengraving 22,23 to determine the distributions of secreted antibody
isotypes and the frequencies of WNV E specific antibodies. There was a range of cells from
our donors with a median of 149,090 antibody secreting cells (range 51,888–375,028) and a
median of 145,601 memory B cells (range 56,862–385,436). Frozen PBMCs were thawed
and maintained in complete RPMI media containing IL-6 (20 ng/mL, Peprotech) and Chk2
inhibitor II (2 μg/mL, Sigma-Aldrich). After resting or stimulation, cells were stained for
viability (Calcein violet AM) and for expression of CD19 (Brilliant Violet® 605), CD20
(Alexa Fluor® 488), CD27 (PerCP-efluor® 710), CD38 (PerCP-efluor® 710) and CD138
(APC), loaded into nanowells, then imaged on an epifluorescence microscope. Separate
microarrays were generated by sealing nanowells with capture slides functionalized with
donkey anti-human Ig (25 μg/mL, Jackson Immunoresearch) or WNV E protein (50 μg/mL,
Aviva Systems Biology). We used a flu specific antibody secreting cell line 39 to determine
non-specific binding events for subsequent background frequency subtraction 23. Isotypespecific information was obtained by staining microarrays with a panel of anti-human IgG1,
IgA, IgG3 and IgM detection antibodies (BD Biosciences and Invitrogen). Microarrays from
WNV E-coated slides were probed with mouse anti-human Igκ and Igλ (BD Biosciences)
detection antibodies. Microarrays were scanned on a GenePix® 4200AL Autoloader
(Molecular Devices), and median fluorescence intensities (MFIs) from bound species were
extracted with GenePix® Pro 6.0 software. Isotype-specific data was analyzed as previously
described 23. Antibodies were considered WNV-E specific if microarray elements were from
wells with viable, CD19+/CD20+/− cells that also satisfied the following criteria: %
saturation ≤ 2, signal-to-noise ratio ≥1, ≥40% of pixels above background + 1 standard
deviation, CV ≤70 and background corrected MFI ≥1500. A fraction of cells from such
wells were recovered with an automated micromanipulator (AVISO CellCellector™, ALS
GmbH), and heavy and light chain variable genes were amplified by single-cell RT-PCR23.
In short, the cells were recovered using a glass capillary mounted on an automated
micromanipulator and a microscope. The glass capillary was placed over the nanowell to
recover the desired MBC or ASC by applying a vacuum. The cell was subsequently released
into a well of a 96 well plate containing water. To subsequently recover antibody heavy and
light chain variable genes, a nested PCR was performed using the primers and protocol
previously published by Stollar et al. 53. These procedures have been described in more
detail by Ogunniyi et al. 24.
Expression and validation of WNV specific antibodies

Author Manuscript

The protocols to clone, express and validate antigen specific antibodies has been previously
described 23,54. In brief, paired heavy and light chain coding sequences were cloned into
vectors for expression as human IgG1. We utilized human embryonic kidney (HEK) 293 T
cells (ATCC) to transiently express the cloned antibodies. Antibodies in culture supernatants
were evaluated for binding on a custom protein microarray consisting of WNV E protein.
Microarrays were scanned on GenePix ® 4200AL and analyzed with GenePix ® Pro 6.0.
Subsequently, the expressed WNV specific antibodies were evaluated by immunoblot and
PRNT assay as described above.
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Library preparation and Next Generation Sequencing

Author Manuscript

To evaluate B cell subsets from recently infected subjects listed, fresh PBMCs were sorted
to isolate plasma cells, naïve and memory B cells, and RNA was isolated for sequencing.
The number of sorted B cells from each subject was a median of 536,792 (range 51,232–
2,108,051). UID barcoded NGS libraries 55 were prepared by AbVitro, Inc from 250 ng of
the extracted RNA of both sorted B cells as well as unsorted PBMCs. NGS libraries were
subsequently sequenced at the MIT BioMicrocenter on the Illumina Miseq platform using
the Illumina 2x300bp sequencing kit according to the manufacturer specifications. PBMCs
from post-convalescent subjects were directly processed without sorting, and libraries were
sequenced using the Illumina 2x150 bp sequencing kit.
High-throughput antibody repertoire sequence analysis

Author Manuscript

Preprocessing was carried out using pRESTO version 0.4 (http://clip.med.yale.edu/
pRESTO) 55 and involved removing primer sequences, filtering based on sequence quality
and annotating sequences with sample information. Following preprocessing, V(D)J
germline segments were determined using IMGT/HighV-QUEST 56. Functional V(D)J
sequences of each subject were combined with WNV-specific sequences and then ChangeO 34 was used to divide the sequences into clonally-related groups by a two-step procedure:
1) sequences were partitioned based on common V gene, J gene, and junction region length,
and 2) within these larger groups, sequences differing from one another by a distance of less
than 0.01 were defined as clones. Distance was measured as the number of point mutations
weighted by a nucleotide substitution probability previously described 57. These data will be
available on Sequence Read Archive (SRA) through the Bioproject accession number
PRJNA270742.

Author Manuscript

Clones for antibodies MIT185 and MIT186 as portrayed in S8 were identified by manual
inspection of S8. To generate S8, for each WNV-specific query sequence, the NGS data was
filtered for sequences with the same V and J germline gene segment. For each of these
sequences, similarity to the query (y-axis) is the Needleman-Wunsch distance on the entire
sequence without end-gap penalties divided by the length of the alignment. The distance
from germline (x-axis) is the Hamming distance (with ambiguous characters not counting as
a mismatch) between the sequence and its germline divided by the number of non-N
nucleotides in the sequence.
The smallest observed WNV-specific clone composed 0.01% of the repertoire. Selection
pressures were quantified using BASELINe 30,58 with the S5F somatic hypermutation
targeting model 57.
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Generation and analysis of lineage trees
Lineage trees were constructed for each clonal group by removing indel positions and then
using maximum parsimony with the dnapars application of PHYLIP 59. This was followed
by recursively replacing inferred ancestors in each tree with descendants having a Hamming
distance of zero from their inferred parent. The trunk length of a clone is defined to be the
branch length from the germline root node to the most recent common ancestor.
Comparisons were made to Ig repertoire sequencing of three individuals who received an

Integr Biol (Camb). Author manuscript; available in PMC 2016 December 30.

Tsioris et al.

Page 12

Author Manuscript

influenza vaccination and had blood drawn at several time-points (8 days, 2 days, and 1 hour
pre-vaccination; 1 hour, 1 day, 3 days, 7 days, 2 weeks, 3 weeks, and 4 weeks postvaccination). Clones were defined in the same way as described above. For the vaccination
data, trunk lengths were only measured for expanded clones, or clones that at some timepoint compose at least 0.05% of the Ig repertoire. Comparisons between trunk lengths were
made using a two-tailed Student’s t-test.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Analysis workflow
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Blood is collected from individuals with a history of infection with WNV and PBMCs were
isolated for further analysis. In parallel subject serum is analyzed using neutralization and
immunoblot assays to determine the individual’s overall response to WNV. Samples of
PBMC are analyzed by microengraving, an integrative single-cell analysis process. WNVspecific antibodies are captured on a protein microarray from single antibody-secreting cells
(ASCs) and single stimulated memory B cells (MBCs). Subsequently, individual WNVspecific MBCs and ASCs identified by microengraving are recovered and the sequences
coding the variable region of the antibody heavy and light chains of their corresponding
antibodies are obtained. Paired heavy and light chain coding sequences are used to clone the
WNV-specific antibodies. The cloned antibodies are evaluated by neutralization and
immunoblot assay. In parallel, the subject antibody repertoire is analyzed by next generation
sequencing (NGS). The NGS data is processed by an integrated bioinformatics pipeline
(pRESTO and Change-O) to identify clones of WNV-specific antibodies.
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Figure 2. B lymphocyte frequencies quantified by flow cytometry
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A) Plot of frequencies of transitional B cells (CD3−, CD19+, CD20+, CD24hi, CD38hi). A
significant difference was found between the frequencies of transitional B cells in recently
infected and post-convalescent individuals. A significant difference was found between the
frequencies of transitional B cells in recently infected and post-convalescent individuals
from a previous study (SDY58). B) Plot of frequencies of naïve B cells (CD3−, CD19+,
CD20+, CD27−). No significant differences were found between the frequencies of naïve B
cells in recently infected and post-convalescent individuals. No significant differences were
found between the frequencies of naïve B cells in recently infected and post-convalescent
individuals from a previous study (SDY58). C) Plot of frequencies of MBCs (CD19+,
CD20+, CD27+). No significant differences were found between the frequencies of MBCs in
recently infected and post-convalescent individuals. A significant difference was found
between the frequencies of MBCs in recently infected and post-convalescent individuals
from a previous study (SDY58). D) Plot of frequencies of plasmablasts (CD3−, CD19+,
CD20−, CD27hi, CD38hi). No significant differences were found between the frequencies of
plasmablasts in recently infected and post-convalescent individuals. A significant difference
was found between the frequencies of plasmablasts in recently infected and postconvalescent individuals from a previous study (SDY58). Multiple blood draws from our
cohort of post-convalescent and recently infected individuals were included in the flow
cytometry analysis. Frequencies are determined as percent of total B lymphocyte parent
population. Statistical analysis was performed by Student’s t-test.
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Figure 3. Persistence and independence of disease severity of West Nile virus-specific B cell
frequencies quantified by single-cell analysis
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A) Plot of frequencies of WNV-specific MBCs. No significant differences were found
between the frequencies of WNV-specific MBCs in recently infected and post-convalescent
individuals. B) Plot of frequencies of WNV-specific MBCs in symptomatic and
asymptomatic individuals, no significant differences were found between the two groups. C)
Plot of frequencies of WNV-specific ASCs by disease status (recent infected vs. postconvalescent). No significant differences were found between the frequencies of antigen
specific ASCs in recently infected and post-convalescent individuals. D) Plot of frequencies
of WNV-specific ASCs by disease severity (symptomatic vs. asymptomatic). No significant
differences were found between the frequencies of antigen specific ASCs in symptomatic vs.
asymptomatic individuals. All WNV antigen specific single-cell events were determined by
microengraving, and shown as events per 100K PBMCs.
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Figure 4. Trunk length analysis of West Nile virus-specific clones in the immunoglobin
repertoire indicates unlikely previous exposure to the virus
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A) Size of WNV-specific clones found in recently infected subjects. No clonal relatives of
WNV-specific sequences were found in post-convalescent subjects. B) Representative plot
of sequence similarity of heavy chain (same V and J segment) identified within the
repertoire as a function of distance of the sequence from germline (x-axis) and the
corresponding “query” WNV-specific sequence (y-axis). An outlier cluster representing a
putative WNV-specific clone is circled. C) Maximum parsimony lineage tree for one WNVspecific clone (MIT187). Each node represents a unique sequence, with size representing the
number of duplicate reads observed. Edge lengths correspond to the number of mutations
between sequences. Shading of the node represents the compartment in which the sequence
was found. The nodes are labeled with the isotypes of the observed sequence (A: IgA, G:
IgG, Q: WNV-specific query sequence from single-cell screening). D) Plot of observed
trunk lengths (number of mutations between germline and most recent common ancestor of
clone). Emerging WNV-specific clones have significantly fewer trunk mutations (Student’s
t-test) compared to size-matched clones found in the same subjects, and to expanded clones
(at least 0.05% of the repertoire) from subjects who received an influenza vaccination.

Integr Biol (Camb). Author manuscript; available in PMC 2016 December 30.

Author Manuscript
post-conv.
post-conv.
post-conv.

44*

26*

21*

67

30

64

65

37

31

59

PC2

PC3

PC4

RI1

RI2

RI3

RI4

RI5

RI6

RI7

recent

recent

recent

recent

recent

recent

Asymp

WNF

WNE

Asymp

WNE

Asymp

WNE

WNF

WNF

Asymp

WNM

Diagnosis

+++++

+++++

+++++

+++

+++++

+++++

++

+++++

+++

++++

+++++

1:40

1:80

1:40

1:40

1:40

1:40

1:80

1:80

1:80

1:640

1:80

PRNT serum titer

WNE, encephalitis;WNF, febrile illness; WNM, meningitis; Asymp, asymptomatic infection. PRNT indicates the dilution of serum needed to achieve 90% reduction of WNV growth in Vero cells.
Immunoblot scale maximum is five +++++, corresponding to the reactivity with a known positive WNV patient serum.

Age of the donor at the time of blood draw.

*

post-conv.

48*

PC1

recent

Disease status

Age at onset/blood draw*
WNV E IgG immunoblot

Author Manuscript

ID

Author Manuscript

Clinical data for West Nile virus-infected subjects.
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Characteristics of West Nile virus neutralizing antibodies.

Author Manuscript

Table 2
Tsioris et al.
Page 20

Integr Biol (Camb). Author manuscript; available in PMC 2016 December 30.

